Truist Financial’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
ISL
PA
Truist Financial's CORT Position: Q2 2026 in Review
Truist Financial increased its Corcept Therapeutics (CORT) stake by 92% in Q2 2026, buying an estimated $476K and bringing the position to 16,449 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1565.
Truist Financial first reported a position in CORT in Q4 2019 and has held it in 19 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.
- Truist Financial held 16,449 shares of Corcept Therapeutics worth $1.43M as of Q2 2026.
- Truist Financial bought 7,879 Corcept Therapeutics shares in Q2 2026, an estimated $476K.
- Corcept Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1565 holding.
- Truist Financial first reported a position in Corcept Therapeutics in Q4 2019 and has held it in 19 quarters since.
- 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.
Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.